Analytical Data
-
Gene name
Otoraplin/OTOR
- Application
-
Alternative Names
FDP; MIAL; MIAL1; Fibrocyte-derived protein; Melanoma inhibitory activity-like protein
-
Species
Mouse
-
Source
E. coli
-
Tag
N-His
-
Purity
Greater than 95% as determined by SDS-PAGE.
-
Uniprot
Q9JIE3
-
Expression Region
Ala17~Thr121
-
Molecular Weight
15kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
Otoraplin (also known as OTOR) is a recombinant protein that has garnered attention in the field of biomedical research due to its potential therapeutic applications. Initially identified for its role in cell differentiation and tissue development, Otoraplin is implicated in various physiological processes, including neural development and immune responses. Recent studies have highlighted its significance in cancer biology, where its altered expression patterns correlate with tumor progression and metastasis. Researchers are keenly investigating the mechanisms by which Otoraplin interacts with cellular pathways, particularly its involvement in signaling cascades that regulate cell growth and apoptosis. Furthermore, the recombinant production of Otoraplin allows for detailed functional studies and the development of potential therapeutic strategies, including its use as a biomarker for disease progression or as a target for novel drug designs. The exploration of Otoraplin's role in pathological conditions opens new avenues for targeted therapies, making it a compelling subject for further investigation in regenerative medicine and oncology. As our understanding of its biological functions deepens, Otoraplin may emerge as a crucial player in developing innovative treatments for various diseases.
